Glyxambi Dosage/Direction for Use

The recommended dose is 1 film-coated tablet of Glyxambi 10 mg/5 mg (10 mg empagliflozin plus 5 mg linagliptin) once daily. The metformin dose should be continued.
Patients with renal impairment: Due to the mechanism of action, decreased renal function will result in reduced efficacy of empagliflozin: In patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² or creatinine clearance (CrCl) ≥60 mL/min, no dose adjustment is required.
In patients with an eGFR <60 mL/min/1.73 m² or CrCl <60 mL/min, Glyxambi should not be used.
In patients with end-stage renal disease or in patients on dialysis, Glyxambi should not be used as empagliflozin is not expected to be effective in these patients.
Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly Patients: No dosage adjustment is recommended based on age. Therapeutic experience in patients aged 85 years and older is limited. Initiation of GLYXAMBI therapy in this population is not recommended.
Paediatric population: The safety and effectiveness of GLYXAMBI in children below 18 years of age have not been established. GLYXAMBI is not recommended for use in patients under 18 years of age.
Combination therapy: When GLYXAMBI is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia.
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.